Gastrointestinal Tumors Clinical Trials

9 recruitingLast updated: May 13, 2026

There are 9 actively recruiting gastrointestinal tumors clinical trials across 2 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable. Top locations include Beijing, Beijing Municipality, China, Chengdu, Sichuan, China, Cleveland, Ohio, United States. Updated daily from ClinicalTrials.gov.


Gastrointestinal Tumors Trials at a Glance

9 actively recruiting trials for gastrointestinal tumors are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Beijing, Chengdu, and Cleveland. Lead sponsors running gastrointestinal tumors studies include Sichuan Baili Pharmaceutical Co., Ltd., Huashan Hospital, and Changhai Hospital.

Browse gastrointestinal tumors trials by phase

Treatments under study

About Gastrointestinal Tumors Clinical Trials

Looking for clinical trials for Gastrointestinal Tumors? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastrointestinal Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastrointestinal Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

GISTGIST - Gastrointestinal Stromal TumorGastrointestinal Tumors+2 more
Kumquat Biosciences Inc.46 enrolled1 locationNCT07406633
Recruiting
Phase 2

Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors

Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
Changhai Hospital40 enrolled1 locationNCT07492693
Recruiting
Phase 1

A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Solid TumorsGastrointestinal Tumors
Sichuan Baili Pharmaceutical Co., Ltd.33 enrolled1 locationNCT07279428
Recruiting
Phase 1

A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

Solid TumorsGastrointestinal Tumors
Sichuan Baili Pharmaceutical Co., Ltd.22 enrolled1 locationNCT07232407
Recruiting
Phase 1

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Gastrointestinal TumorsPersonalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy
Ruijin Hospital40 enrolled1 locationNCT07067385
Recruiting

Combined Screening for Gastrointestinal Tumors

Gastrointestinal Tumors
Zhejiang Cancer Hospital200,000 enrolled2 locationsNCT06478030
Recruiting
Phase 2

The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors

Gastrointestinal Tumors
Huashan Hospital40 enrolled1 locationNCT06775080
Recruiting
Not Applicable

PD-L1 Targeting Molecular Imaging of Solid Tumors

Gastrointestinal Tumors
Peking University Cancer Hospital & Institute20 enrolled1 locationNCT04629326
Recruiting
Early Phase 1

BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

Gastrointestinal Tumors
BioSyngen Pte Ltd14 enrolled1 locationNCT06152757